Last reviewed · How we verify

Sofosbuvir and ribavirin

Kirby Institute · FDA-approved active Small molecule Quality 5/100

Sofosbuvir and ribavirin is a Small molecule drug developed by Kirby Institute. It is currently FDA-approved. Also known as: Sovaldi, Copegus.

At a glance

Generic nameSofosbuvir and ribavirin
Also known asSovaldi, Copegus
SponsorKirby Institute
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Sofosbuvir and ribavirin

What is Sofosbuvir and ribavirin?

Sofosbuvir and ribavirin is a Small molecule drug developed by Kirby Institute.

Who makes Sofosbuvir and ribavirin?

Sofosbuvir and ribavirin is developed and marketed by Kirby Institute (see full Kirby Institute pipeline at /company/kirby-institute).

Is Sofosbuvir and ribavirin also known as anything else?

Sofosbuvir and ribavirin is also known as Sovaldi, Copegus.

What development phase is Sofosbuvir and ribavirin in?

Sofosbuvir and ribavirin is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing